O
10.27
-0.85 (-7.64%)
| Penutupan Terdahulu | 11.12 |
| Buka | 11.06 |
| Jumlah Dagangan | 3,236,189 |
| Purata Dagangan (3B) | 3,622,518 |
| Modal Pasaran | 2,187,997,696 |
| Harga / Jualan (P/S) | 26.47 |
| Harga / Buku (P/B) | 7.02 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 4 Nov 2025 |
| Margin Operasi (TTM) | -597.47% |
| EPS Cair (TTM) | -1.11 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -27.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 28.66% |
| Nisbah Semasa (MRQ) | 10.22 |
| Aliran Tunai Operasi (OCF TTM) | -145.46 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -87.96 M |
| Pulangan Atas Aset (ROA TTM) | -27.21% |
| Pulangan Atas Ekuiti (ROE TTM) | -57.19% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Ocular Therapeutix, Inc. | Menaik | Menaik |
AISkor Stockmoo
1.3
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -0.5 |
| Purata | 1.25 |
|
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 3.82% |
| % Dimiliki oleh Institusi | 87.01% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Summer Road Llc | 30 Sep 2025 | 12,579,657 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 21.00 (HC Wainwright & Co., 104.48%) | Beli |
| 21.00 (Chardan Capital, 104.48%) | Beli | |
| Median | 21.00 (104.48%) | |
| Rendah | 20.00 (Needham, 94.74%) | Beli |
| Purata | 20.67 (101.27%) | |
| Jumlah | 3 Beli | |
| Harga Purata @ Panggilan | 16.06 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Chardan Capital | 09 Dec 2025 | 21.00 (104.48%) | Beli | 15.95 |
| 05 Nov 2025 | 21.00 (104.48%) | Beli | 10.81 | |
| HC Wainwright & Co. | 08 Dec 2025 | 21.00 (104.48%) | Beli | 16.11 |
| 25 Nov 2025 | 19.00 (85.00%) | Beli | 12.13 | |
| Needham | 08 Dec 2025 | 20.00 (94.74%) | Beli | 16.11 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 05 Feb 2026 | Pengumuman | Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights |
| 23 Jan 2026 | Pengumuman | Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
| 21 Jan 2026 | Pengumuman | Ocular Therapeutix™ Appoints David W. Robinson as Global Chief Commercial Officer |
| 08 Dec 2025 | Pengumuman | Ocular Therapeutix™ Announces Plans to Accelerate NDA Submission Timeline for AXPAXLI™ in Wet AMD |
| 05 Dec 2025 | Pengumuman | Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
| 24 Nov 2025 | Pengumuman | Ocular Therapeutix™ Announces First Patient Randomized in HELIOS-3 Phase 3 Registrational Program for AXPAXLI™ in NPDR |
| 12 Nov 2025 | Pengumuman | Ocular Therapeutix™ to Participate in November and December Investor Conferences |
| 07 Nov 2025 | Pengumuman | Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |